Investigating how damaged lung cells contribute to lung scarring
Oxidized Phospholipids Derived from Apoptotic Pneumocytes Drives Macrophage Activation and Initiates Lung Fibrosis
This study is looking into how lung damage leads to scarring in conditions like Idiopathic Pulmonary Fibrosis (IPF) and aims to find new ways to help slow down this process, with the help of patients who can share their samples or information.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10842349 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms behind lung fibrosis, particularly in conditions like Idiopathic Pulmonary Fibrosis (IPF), which severely impacts patients' lives. It examines how injury and death of specific lung cells lead to inflammation and scarring in the lungs. By studying the role of oxidized phospholipids released from these damaged cells, the research aims to uncover new therapeutic targets that could help slow or prevent the progression of fibrosis. Patients may be involved in providing samples or data to help elucidate these pathways.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with Idiopathic Pulmonary Fibrosis or other forms of lung fibrosis.
Not a fit: Patients with acute lung injuries not related to fibrosis or those without any lung conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve outcomes for patients with lung fibrosis.
How similar studies have performed: Previous research has shown promising results in understanding the role of cell injury in fibrosis, indicating that this approach could yield valuable insights.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Kim, Kevin Keewoun — University of Michigan at Ann Arbor
- Study coordinator: Kim, Kevin Keewoun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.